JERUSALEM (Reuters) - Teva Pharmaceutical Industries reported a smaller than expected rise in first-quarter profit citing higher impairments of tangible assets, while sales of copycat medicines and its branded drugs to treat migraines and Huntington's disease rose.

The world's largest generic drugmaker said on Wednesday it earned 48 cents diluted share excluding one-time items in the January-March quarter, up from 40 cents per share a year earlier. Revenue rose 4% to $3.82 billion.

Analysts had forecast earnings of 51 cents per share ex-items for the Israel-based company on revenue of $3.73 billion, LSEG I/B/E/S data showed.